Vaccination approach to anti-angiogenic treatment of cancer.

  title={Vaccination approach to anti-angiogenic treatment of cancer.},
  author={Madelon Q Wentink and Elisabeth J. M. Huijbers and Tanja D. de Gruijl and Henk M. W. Verheul and A K Olsson and Arjan W Griffioen},
  journal={Biochimica et biophysica acta},
  volume={1855 2},
Improvement of patient survival by anti-angiogenic therapy has proven limited. A vaccination approach inducing an immune response against the tumor vasculature combines the benefits of immunotherapy and anti-angiogenesis, and may overcome the limitations of current anti-angiogenic drugs. Strategies to use whole endothelial cell vaccines and DNA- or protein vaccines against key players in the VEGF signaling axis, as well as specific markers of tumor endothelial cells, have been tested in… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.


Publications citing this paper.
Showing 1-10 of 10 extracted citations

Fibronectin-targeted drug delivery in cancer.

Advanced drug delivery reviews • 2016
View 1 Excerpt

Anti-angiogenic alternatives to VEGF blockade

Clinical & Experimental Metastasis • 2015
View 1 Excerpt


Publications referenced by this paper.
Showing 1-10 of 168 references


F. S. Hodi, D. Lawrence, +10 authors G. F. Murphy
Rodig, E.F. Velazquez, M.C. Mihm Jr., S. Russell, P.J. DiPiro, J.T. Yap, N. Ramaiya, A.D. Van den Abbeele, M. Gargano, D. McDermott, Bevacizumab plus ipilimumab in patients with metastatic melanoma, Cancer Immunol. Res. 2 • 2014
View 3 Excerpts
Highly Influenced


J. Yuan, J. Zhou, Z. Dong, S. Tandon
Kuk, K.S. Panageas, P.Wong, X.Wu, J. Naidoo, D.B. Page, J.D.Wolchok, F.S. Hodi, Pretreatment serumVEGF is associatedwith clinical response and overall survival in advanced melanoma patients treated with ipilimumab, Cancer Immunol. Res. 2 • 2014


J. F. Vansteenkiste, B. Cho, +17 authors N. K. Altorki
a double-blind, randomized, placebo-controlled phase III study to test the efficacy of the RecMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC), Ann. Oncol. 25 (suppl 4) • 2014
View 3 Excerpts


A. Griffioen, A. Weiss, R. Berndsen, U. Abdul, M. Te Winkel
Nowak-Sliwinska, The Emerging Quest for the Optimal Angiostatic Combination Therapy • 2014
View 1 Excerpt

Recognition of the Tumor Vasculature as a Target for Cancer Vaccination

A. W. Griffioen
View 1 Excerpt

Similar Papers

Loading similar papers…